Infinium Pharmachem , engaged in the manufacturing of Pharma Intermediates and APIs, Iodine derivatives has reported net profit of Rs. 9.49 crore for FY23, with Y-o-Y growth of 55.4% as compared to the net profit of Rs. 6.10 crore in FY22. Revenue from Operations grew 15.24% to Rs. 114.22 crore in FY23 as against revenue of Rs. 99.12 crore reported in FY22. Profit Before Tax during FY23 grew 50% to Rs. 12.95 crore as against Profit before Tax of Rs. 8.63 crore in FY22. EPS for FY23 is Rs. 18.67 per share.
Established in the year 2003, Infinium Pharmachem manufactures and supply wide range of superior quality Iodine derivatives and APIs.
Sanjaykumar Patel, Managing Director, Infinium Pharmachem said, “Company has reported excellent numbers for FY 2023. We feel proud to inform all our stakeholders that the company is progressing well on its long-term growth roadmap. Company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue and expect to get further boost in coming years.”
In the month of March 2023, company successfully completed its Rs. 25.25 crore SME IPO on NSE Emerge. The public issue is for 18.75 lakh shares of face value of Rs 10 per equity share for a cash price of Rs. 135 per equity share.
In the year 2022, company incorporated a subsidiary company – Infinium Green Energy Private in bio-fuel segment for backward integration. Infinium Green Energy Private is engaged in the business of manufacturing eco-friendly industrial fuel from agro waste.
Infinium Pharmchem holds 51% equity in Infinium Green Energy. The company has started commercial production from 14th May, 2023. The Company is also poised to make significant contribution towards objectives of Government like “Atmanirbhar Bharat”, maximizing income of farmers and protection of environment.
The company has its manufacturing plant at GIDC Sojitra, Anand Gujarat, India. The Company got certified as ISO 9001-2015 in the year 2017. The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customised and fully confidential solutions to its clients.